酮康唑预防实验性念珠菌性阴道炎
Ketoconazole in the prevention of experimental candidal vaginitis.
作者信息
Sobel J D, Muller G
出版信息
Antimicrob Agents Chemother. 1984 Feb;25(2):281-2. doi: 10.1128/AAC.25.2.281.
Abstract
The prophylactic and therapeutic activities of ketoconazole were evaluated in rats inoculated intravaginally with Candida albicans. Daily doses of 2.5 mg/kg initiated 48 h before challenge and continued for 48 h thereafter protected 80% of the rats against infection. A similar result in rats with established infection was attained with daily doses of 5.0 mg/kg.
摘要
在经阴道接种白色念珠菌的大鼠中评估了酮康唑的预防和治疗活性。在攻击前48小时开始每日给予2.5mg/kg的剂量，并在此后持续48小时，可保护80%的大鼠免受感染。对于已感染的大鼠，每日给予5.0mg/kg的剂量也取得了类似的结果。
相似文献
1
Ketoconazole in the prevention of experimental candidal vaginitis.
Antimicrob Agents Chemother. 1984 Feb;25(2):281-2. doi: 10.1128/AAC.25.2.281.
2
Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis.
Antimicrob Agents Chemother. 1984 Aug;26(2):266-7. doi: 10.1128/AAC.26.2.266.
3
Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis.
Obstet Gynecol. 1985 Mar;65(3):435-40.
4
Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.
Antimicrob Agents Chemother. 1985 May;27(5):832-5. doi: 10.1128/AAC.27.5.832.
5
Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy.
N Engl J Med. 1986 Dec 4;315(23):1455-8. doi: 10.1056/NEJM198612043152305.
6
Activity of SM-4470, a new imidazole derivative, against experimental fungal infections.
Antimicrob Agents Chemother. 1986 Sep;30(3):366-9. doi: 10.1128/AAC.30.3.366.
7
Comparison of ketoconazole, Bay N7133, and Bay L9139 in the treatment of experimental vaginal candidiasis.
Antimicrob Agents Chemother. 1983 Sep;24(3):434-6. doi: 10.1128/AAC.24.3.434.
8
Comparisons of ketoconazole, PR 969-566, PR 967-234, and PR 967-248 as antifungals in vitro and in the rat model of candidal vaginitis based on efficacy/safety profiles.
Ann N Y Acad Sci. 1988;544:387-91. doi: 10.1111/j.1749-6632.1988.tb40431.x.
9
The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole.
Genitourin Med. 1992 Jun;68(3):174-6. doi: 10.1136/sti.68.3.174.
10
Synergistic anti-candidal activity of tetrandrine on ketoconazole: an experimental study.
Planta Med. 2010 Jan;76(1):53-61. doi: 10.1055/s-0029-1185973. Epub 2009 Jul 30.
引用本文的文献
1
The vaginal mycobiome: A contemporary perspective on fungi in women's health and diseases.
Virulence. 2017 Apr 3;8(3):342-351. doi: 10.1080/21505594.2016.1237332. Epub 2016 Sep 22.
2
In Vitro and In Vivo Activities of Essential Oil from the Seed of Anethum graveolens L. against Candida spp.
Evid Based Complement Alternat Med. 2011;2011:659704. doi: 10.1155/2011/659704. Epub 2011 May 11.
3
A novel itraconazole bioadhesive film for vaginal delivery: design, optimization, and physicodynamic characterization.
AAPS PharmSciTech. 2009;10(3):951-9. doi: 10.1208/s12249-009-9288-0. Epub 2009 Jul 24.
4
Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: 2. Factors that may have influenced the marked changes in sales volumes during the 1990s.
Infect Dis Obstet Gynecol. 2004 Jun;12(2):99-108. doi: 10.1080/10647440400003972.
5
Microscopic features of vaginal candidiasis and their relation to symptomatology.
Sex Transm Infect. 1999 Dec;75(6):417-9. doi: 10.1136/sti.75.6.417.
6
Critical role of germ tube formation in the pathogenesis of candidal vaginitis.
Infect Immun. 1984 Jun;44(3):576-80. doi: 10.1128/iai.44.3.576-580.1984.
7
Isolation of a germ-tube-forming revertant from Candida albicans B311V6.
Infect Immun. 1986 Jul;53(1):13-5. doi: 10.1128/iai.53.1.13-15.1986.
8
Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing.
J Clin Microbiol. 1988 Nov;26(11):2307-12. doi: 10.1128/jcm.26.11.2307-2312.1988.
9
Selection of orally active antifungal agents from 3,5-substituted isoxazolidine derivatives based on acute efficacy-safety profiles.
Antimicrob Agents Chemother. 1989 Jun;33(6):895-905. doi: 10.1128/AAC.33.6.895.
本文引用的文献
1
The mechanism of action of the new antimycotic ketoconazole.
Am J Med. 1983 Jan 24;74(1B):2-8. doi: 10.1016/0002-9343(83)90507-7.
2
Treatment of vaginal candidiasis with ketoconazole, a new, orally active, antimycotic.
Eur J Obstet Gynecol Reprod Biol. 1979 Aug;9(4):253-9. doi: 10.1016/0028-2243(79)90065-0.
Zotero 插件